インフォショップ ホームへ 株式会社グローバルインフォメーション
サイトマップ
その他のカテゴリ

商品カタログ

医療/バイオの調査資料販 MEDINFO.JP

バイオシミラー特集
バイオシミラー特集ページ バイオシミラーに関連したレポートを紹介致します。

Global Pharmaceuticals Research & Manufacturing 公式サイト

Translational Cancer Medicine 公式サイト

Outsourcing Asia Summit 2009 公式サイト

Global Healthcare Congress 2009 公式サイト

BioMedical Asia 2009 公式サイト

China 2009 Pharmaceutical R&D Summit 公式サイト

Drug Discovery & Development of Innovative Therapeutics Japan 2009 公式サイト

Drug Discovery & Development of Innovative Therapeutics 2009 公式サイト
English Korean Chinese
【 英文市場調査報告書 】

世界の抗感染薬Vol.II:抗菌剤

Anti Infectives, Vol II: Antibacterials

商品コード : 50805 Kalorama Information
出版日 : 2007/04
発行 : Kalorama Information
電話でのお問い合わせ
価格情報
概要 原文目次
※この商品は英文にてご提供いたします。

Abstract

Antibacterial drugs have turned bacterial infections into treatable ailments rather than the life-threatening conditions they once were. But the effectiveness of many antibiotics is being reduced as more and more types of bacteria become resistant to them. Because of antibiotic resitance and other changing dynamics, knowledge of issues and trends is necessary to operate the antibacterials market.

Kalorama' s Anti-Infectives, Vol. II: Antibacterials provides extensive detail on the anti-bacterial market, including the following critical trends:

  • Drug resistance and Interactions
  • Antibiotic Abuse
  • Antibiotic Cycling
  • Addressing Market Trends
  • Antibiotic Use in Agriculture
  • Antibiotic Education
  • Children and Bacterial Resistance
  • The Elderly and Bacterial Resistance
  • Compromised Individuals and Bacterial Resistance
  • Screening Hospital Patients
  • Side Effects of Antibiotics
  • Partnerships and Alliances
  • Environment and Drug Resistance
  • Methicillin Resistant Staphylococcus Aureus

In this, the second volume of Kalorama Information' s Anti-Infective Markets series, the antibacterial drug market is broken down into seven general categories based on drug class:

  • cephalosporins
  • macrolides
  • penicillins
  • quinolones
  • sulfonamides
  • tetracyclines
  • other misc. antibiotics

There is a significant trend shift occuring in the antibacterials market since Kalorama Information' s last edition in 2005. Anti-Infectives Vol. II: Antibacterials covers that shift in detail. For each marketplace segment, Market Size, Growth and Share are provided, and revenue is forecasted to 2011 are provided. Current products are discussed and new pipeline products are assessed. In total, over 100 Tables and Figures provide accessible data on this growing market, a depth of coverage unsurpassed by any competitive study.

The following companies are profiled as part of this report:

  • Abbott Laboratories
  • AstraZeneca
  • Bayer Schering Pharma
  • Cubist Pharmaceuticals
  • Daiichi Sankyo
  • GlaxoSmithKline
  • Johnson & Johnson Group
  • King Pharmaceuticals
  • Merck & Company, Inc.
  • Pfizer, Inc.
  • Roche
  • Sanofi-Aventis
  • Wyeth

Table of Contents

Executive Summary

  • Introduction
  • Scope and Methodology
  • Size and Growth of the Market
  • Issues and Trends Affecting Market
  • Leading Competitors

Introduction The World Market for Anti-Infectives Volume 2:

  • Antibacterial Drugs
  • Introduction to pathogens
    • Classification of Antibacterial Organisms
    • Antimicrobial Spectrum
    • Bacterial Resistance
    • Principles of Anti-infective Therapy
    • Infecting Organism
    • Antibiotic Sensitivity Testing
    • Site of Infection
    • Host Defenses and Organ Function
    • Antibiotic Pharmacokinetics
    • Monitoring Therapy
    • Combination Therapy and Prophylactic Use
  • Demographics and Statistics

Issues and Trends Affecting the Antibacterial Drug Market

  • introduction
  • Drug Resistance and Interactions
  • Antibiotic Abuse
  • Antibiotic Cycling
  • addressing market trends
  • Antibiotic use in Agriculture
  • Antibiotic Education
  • Children and Bacterial resistance
  • The Elderly and Bacterial Resistance
  • Compromised Individuals and Bacterial Resistance
  • Screening Hospitalized patients
  • Side Effects of Antibiotics
  • Partnerships and Alliances
  • Environment and Drug Resistance
  • Methicillin-resistant Staphylococcus Aureus (MRSA)

Cephalosporin Antibiotics

  • Overview
  • Description of Products
    • First Generation Cephalosporins
    • Cephalexin (Keflex, Advancis Pharmaceuticals)
    • Cefazolin (Ancef, GlaxoSmithKline; Cefamezin, Astellas)
    • Cefadroxil (Duricef, Bristol-Myers Squibb/Warner Chilcot)
    • Second Generation Cephalosporins
    • Cefuroxime (Ceftin, GlaxoSmithKline)
    • Cefoxitin (Mefoxin, Merck)
    • Third Generation Cephalosporins
    • Cefotaximen (Claforan offered by Sanofi-Aventis)
    • Cefoperazone (Cefobid, Pfizer)
    • Ceftibutin (Cedax, Shionogi)
    • Ceftizoxime (Cefizox, Astellas)
    • Ceftriaxone (Rocephin, Roche)
    • Ceftazidime (Fortaz, GlaxoSmithKline)
    • Cefixime (Suprax, Wyeth/Lupin Pharmaceuticals)
    • Cefpodoxime (Vantin, Pfizer)
    • Fourth Generation Cephalosporins
    • Cefepime (Maxipime, Bristol-Myers Squibb)
  • Generic Drug Impact and Availability
  • Research and Development
  • Market Size and Growth
  • Competitive Analysis

Macrolide Antibiotics

  • Overview
  • Description of Products
    • Azithromycin (Zithromax, Pfizer; Zmax, Pfizer)
    • Clarithromycin (Biaxin, Abbott Laboratories)
    • Erythromycin (Erythrocin, Abbott Laboratories; EryPed, Abbott Laboratories)
    • Telithromycin (Ketek, Sanofi-Aventis)
  • Generic Drug Impact and Availability
  • Research and Development
  • Market Size and Growth
  • Competitive Analysis

Penicillin Antibiotics

  • Overview
  • Natural Penicillins
  • Penicillinase-Resistant Penicillins
  • Broad -Spectrum Penicillins
  • Extended-Spectrum Penicillins

Description of Products

  • Natural Penicillins
  • Penicillin G (Bicillin, King Pharmaceuticals; Pfizerpen, Pfizer)
  • Penicillinase-resistant Penicillins
  • Cloxacillin (Cloxapen, GlaxoSmithKline)
  • Oxacillin (Bactocill, GlaxoSmithKline)
  • Broad-spectrum Penicillins
  • Amoxicillin (Augmentin, GlaxoSmithKline; Amoxil,GlaxoSmithKline)
  • Ampicillin (Unasyn, Pfizer)
  • Extended-spectrum Penicillins
  • Carbenicillin (Geocillin, Pfizer)
  • Piperacillin (Pipracil, Wyeth; Zosyn, Wyeth)
  • Ticarcillin (Timentin, GlaxoSmithKline)
  • Generic Drug Impact and Availability
  • Research and Development
  • Market Size and Growth
  • Competitive Analysis

Quinolone Antibiotics

  • Overview
  • Description of Products
    • Ciprofloxacin (Cipro, Bayer; Proquin XR, Depomed)
    • Gemifloxacin (Factive, LG Chem Ltd. and Oscient Pharmaceuticals)
    • Lomefloxacin (Maxaquin, Unimed)
    • Nalidixic (NegGram, Sanofi-Aventis)
    • Norfloxacin (Noroxin, Merck)
    • Ofloxacin (Floxin, Ortho-McNeil)
    • Moxifloxicin (Avelox, Bayer; Vigamox, Alcon)
    • Levofloxacin (Levaquin, Ortho-McNeil; Tavanic, Sanofi-Aventis; Cravit, Daiichi Sankyo; Quixin, Santen)
    • Gatifloxacin (Zymar, Allergan/Kyorin)
    • Trovafloxacin (Trovan, Pfizer)
  • Generic Drug Impact and Availability
  • Research and Development
  • Market Size and Growth
  • Competitive Analysis

Sulfonamide Antibiotics

  • Overview
  • Description of Products
  • Sulfisoxazole (Gantrisin Pediatric, Roche)
    • Oxytetracycline/Sulfamethizole/Phenazopyridine (Urobiotic, Pfizer)
    • Erythromycin ethylsuccinate and Sulfisoxazole acetyl (Pediazole, Ross)
    • Dapsone (Aczone Gel, QLT USA-Tolmar Inc.)
  • Research and Development
  • Market Size and Growth
  • Competitive Analysis

Tetracycline Antibiotics

  • Overview
  • Description of Products
  • Generic Drug Impact and Availability
  • Research and Development
  • Market Size and Growth
  • Competitive Analysis

Other Miscellaneous Antibiotics

  • Overview
  • Description of Products
  • Aminoglycosides
    • Amikacin Sulfate (Amikin, Bristol-Myers Squibb)
    • Kanamycin Sulfate (Kantrex, Bristol-Myers Squibb)
    • Neomycin Sulfate (Neo-fradin, X Gen Pharms)
    • Streptomycin Sulfate (Streptomycin, Pfizer)
    • Lincomycin
    • Clindamycin (Cleocin, Pfizer; Clindesse, KV Pharmaceutical Company; Evoclin, Connetics Corp.; Ziana Gel, Medicis/Dow)
    • Chloramphenicol
    • Chloramphenicol (Chloromycetin,Pfizer)
    • Glycopeptide
    • Vancomycin (Vancocin, Viropharma)
    • Monobactams
    • Aztreonam (Azactam, Bristol-Myers Squibb)
    • Carbapenems
    • Imipenem/cilastatin (Primaxin, Merck)
    • Meropenem (Merrem, AstraZeneca)
    • Metronidazole
    • Metronidazole (Flagyl, Pfizer; Pylera, Axcan; Metrogel-Vaginal, 3M Pharmaceuticals; MetroGel, Galderma)
    • Antituberculars
    • Rifampicin (Rifater, Sanofi-Aventis)
    • Capreomycin (Capastat sulfate, Eli Lilly & Co.)
    • Ethionamide (Trecator SC, Wyeth)
    • Aminosalicylic acid granules (Paser Granules, Jacobus Pharmaceutical)
    • Cycloserine (Seromycin, Eli Lilly & Co.)
    • Antileprotics
    • Dapsone (Dapsone, Jacobus)
    • Oxazolidinones
    • Linezolid (Zyvox, Pfizer)
    • Ketolides
    • Telithromycin (Ketek, Sanofi-Aventis)
    • Lipopeptides
    • Daptomycin (Cubicin, Cubist Pharmaceutical)
    • Glycyclines
    • Tigecycline (Tygacil, Wyeth)
    • Generic Drug Impact and Availability
    • Research and Development
    • Market Size and Growth
    • Competitive Analysis

Corporate Profiles

  • Introduction
  • Abbott Laboratories
  • AstraZeneca plc
  • Bayer Schering Pharma AG
  • Cubist Pharmaceuticals, Inc
  • Daiichi Sankyo Co., Ltd.
  • GlaxoSmithKline
  • Johnson & Johnson Group
  • King Pharmaceuticals, Inc.
  • Merck & Company, Inc.
  • Pfizer, Inc.
  • Roche
  • Sanofi-Aventis
  • Wyeth

Company Names and Addresses

概要 原文目次
※この商品は英文にてご提供いたします。
【 英文市場調査報告書 】
世界の抗感染薬Vol.II:抗菌剤
Anti Infectives, Vol II: Antibacterials
出版日 : 2007/04
電話でのお問い合わせ
この商品について問い合わせる
この商品のサンプル(抜粋)を依頼する
価格

※ドル建て価格の商品のお支払いは、為替レート (TTS: 94.69) 換算による円建てのご請求書にて承ります。

US $ 5,990 換算 -> ¥ 567,193 (税抜) PDF by E-mail (Global Site License)
US $ 3,795 換算 -> ¥ 359,348 (税抜) PDF by E-mail (Single User License) & Hard Copy
US $ 3,395 換算 -> ¥ 321,472 (税抜) Hard Copy
US $ 2,995 換算 -> ¥ 283,596 (税抜) PDF by E-mail (Single User License)
商品コード : 50805